The cancer vaccine roller coaster
暂无分享，去创建一个
[1] Malorye Allison. Trouble at the office , 2008, Nature Biotechnology.
[2] R. Figlin,et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial , 2008, The Lancet.
[3] Axel Hoos,et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] T. Whiteside,et al. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. , 2006, Seminars in cancer biology.
[5] H. Mellstedt,et al. Clinical results of vaccine therapy for cancer: learning from history for improving the future. , 2006, Advances in cancer research.
[6] M. Peshwa,et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.